StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

Creative Medical Technology Gets Nasdaq Notice Over Sub-$1 Bid Price

Creative Medical Technology Holdings said Nasdaq notified it that its stock traded below $1.00 for 30 straight business days, giving it until May 10, 2027 to regain compliance.

What happened

Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ), a Phoenix-based biotechnology company, said in a Form 8-K filed Nov. 13, 2026 that it received a letter from Nasdaq dated Nov. 10, 2026 stating the company is not in compliance with Nasdaq Listing Rule 5550(a)(2).

That rule requires a minimum closing bid price of $1.00 per share. Nasdaq said CELZ's closing bid had been below that level for 30 consecutive business days.

The company said the notice has no immediate impact on its listing. Shares closed at $0.5281 on the event date, down 14.35% from the prior close of $0.6166, according to the price data.

The grace period

Under Nasdaq rules, the company has a 180-day grace period running until May 10, 2027, during which it can regain compliance if its closing bid price is $1.00 or more for at least ten consecutive business days.

The company said it may be eligible for a second 180-day grace period if it meets Nasdaq's initial listing standards for the Nasdaq Capital Market, other than the minimum bid price requirement.

Creative Medical Technology said it "intends to actively monitor the bid price" through May 10, 2027 and "will consider available options to regain compliance." The filing does not specify which options the company is considering.

What this means

A minimum bid price rule is a listing standard, not a judgment about the business. Nasdaq requires most stocks on its markets to trade at $1.00 or above because very low-priced shares can be harder to trade and more prone to sharp swings. Rule 5550(a)(2) is the specific provision for the Nasdaq Capital Market.

A "bid price" is the highest price a buyer is currently willing to pay. Nasdaq tracks the closing bid, not the last trade, so the 30-day count is based on where buyers were bidding at the end of each session.

The 8-K is the form public companies use to disclose material events to investors between quarterly reports. Item 3.01 is the specific section reserved for delisting notices and failures to meet continued listing standards. Filing it does not mean the stock is being delisted; it starts a defined compliance clock.

If the company does not regain compliance by the end of the grace period and is not granted an extension, Nasdaq would move to delist the stock. The filing lays out the timetable and the ten-day cure threshold but does not predict which path the company will take.

Creative Medical Technology describes itself in the filing under the biological products category. The notice concerns only the share price, and the filing gives no reason for the decline in the stock.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.